Adb-fubinaca

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ADB-FUBINACA: a synthetic cannabinoid; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	70969086
CHEBI ID	189489
SCHEMBL ID	13688869

Synonyms (12)

Synonym
adb-fubinaca
CHEBI:189489
1445583-51-6
n-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-luorophenyl)methyl]indazole-3-carboxamide
n-(1-(aminocarbonyl)-2,2-dimethylpropyl)-1-((4-fluorophenyl)methyl)-1h-indazole-3-carboxamide
dea no 7010
SCHEMBL13688869
n-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1h-indazole-3-carboxamide
Q15708300
n-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-[(4-fluorophenyl)methyl]-1h-indazole-3-carboxamide
DTXSID701009981
n-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide

Research Excerpts

Bioavailability

Excerpt	Reference	Relevance
"AB-FUBINACA and ADB-FUBINACA are orally bioavailable with rapid onset of toxicity after ingestion."	( Supraventricular tachycardia and acute confusion following ingestion of e-cigarette fluid containing AB-FUBINACA and ADB-FUBINACA: a case report with quantitative analysis of serum drug concentrations. Chong, YK; Lam, RPK; Leung, SC; Mak, TWL; Tang, MHY; Tsui, MSH, 2017)	1.01

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

Class	Description
indazoles
aromatic amide	An amide in which the amide linkage is bonded directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (9)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	8 (88.89)	24.3611
2020's	1 (11.11)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	37.49 (24.57)
Research Supply Index	2.30 (2.92)
Research Growth Index	4.55 (4.65)
Search Engine Demand Index	50.49 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (37.49)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (11.11%)	6.00%
Case Studies	6 (66.67%)	4.05%
Observational	0 (0.00%)	0.25%
Other	2 (22.22%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	4.9	9	0	indazole
cathinone cathinone: alkaloid from khat shrub, Catha edulis; RN given refers to parent cpd without isomeric designation. cathinone : The S stereoisomer of 2-aminopropiophenone.	2.21	1	0	2-aminopropiophenone; monoamine alkaloid	central nervous system stimulant; psychotropic drug

Condition	Relationship Strength	Studies
Heart Disease, Ischemic [description not available]	3.33	1
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	8.33	1
Drug Overdose Accidental or deliberate use of a medication or street drug in excess of normal dosage.	3.83	3
Chemical Dependence [description not available]	2.58	2
Anoxia-Ischemia, Brain [description not available]	2.21	1
Arteriosclerosis, Coronary [description not available]	2.21	1
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	2.21	1
Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.	2.21	1
Pneumonia Infection of the lung often accompanied by inflammation.	2.21	1
Substance-Related Disorders Disorders related to substance use or abuse.	2.58	2
Hypoxia-Ischemia, Brain A disorder characterized by a reduction of oxygen in the blood combined with reduced blood flow (ISCHEMIA) to the brain from a localized obstruction of a cerebral artery or from systemic hypoperfusion. Prolonged hypoxia-ischemia is associated with ISCHEMIC ATTACK, TRANSIENT; BRAIN INFARCTION; BRAIN EDEMA; COMA; and other conditions.	2.21	1
Atrioventricular Conduction Block [description not available]	2.89	3
Coma A profound state of unconsciousness associated with depressed cerebral activity from which the individual cannot be aroused. Coma generally occurs when there is dysfunction or injury involving both cerebral hemispheres or the brain stem RETICULAR FORMATION.	7.89	3
Fasting Hypoglycemia HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.	2.89	3
Absence Seizure [description not available]	2.89	3
Hypoglycemia A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.	7.89	3
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	7.89	3
Atrioventricular Block Impaired impulse conduction from HEART ATRIA to HEART VENTRICLES. AV block can mean delayed or completely blocked impulse conduction.	7.89	3
Bewilderment [description not available]	2.15	1
Tachycardia, Supraventricular A generic expression for any tachycardia that originates above the BUNDLE OF HIS.	2.15	1
Foreign Bodies Inanimate objects that become enclosed in the body.	2.17	1
Cardiomyopathy, Congestive [description not available]	2.21	1
Edema, Pulmonary [description not available]	2.21	1
Cardiomyopathy, Dilated A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein.	2.21	1
Pulmonary Edema Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening.	2.21	1

chemdatabank.com